RE:Liking What We See, Initiating With OW & $9 PT - Summary Upcoming Catalysts and Events
Exhibit 9: Catalysts and Events Calendar
Date Driver Upcoming Event
2022+
*2022+ Trogarzo (ibalizumab) Uptake of IV push formulation in HIV (FDA approved on Oct. 3, 2022)
*2022+ TH1902 (PDC) Potential out-licensing of the development and commercialization rights for Greater China
*2022+ Tesamorelin F8 (NASH) Potential partnership to launch Phase 3 clinical trials
*Early 2023 Trogarzo (ibalizumab) Data for intramuscular (IM) formulation in HIV
*Early 2023 Trogarzo (ibalizumab) Filing of intramuscular (IM) formulation in HIV
*End of 1Q23 TH1902 (PDC) Complete patient enrollment in Phase 1b basket trial (target is ~70 patients)
3Q23 Egrifta SV Patent protection in lipodystrophy expires
4Q23 Tesamorelin F8 (NASH) Filing of new formulation
*1Q24 Tesamorelin F8 (NASH) Approval and launch of new formulation
March 2030 Trogarzo (ibalizumab) Regulatory exclusivity in the US expires
2033 Tesamorelin F8 US formulation patent expires
2034 Tesamorelin F8 EU formulation patent expires
2040 Tesamorelin (NAFLD/NASH) Two US patents expire
*- events are those that we believe have the potential to move the stock.
Event timing estimates based on company guidance unless